This bill would amend title 35 to create an Interagency Task Force on Patents joining the United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA). The task force would coordinate information sharing and provide technical assistance on patent matters involving human drugs and biological products, with a formal memorandum of understanding between agencies.
A four-year after-enactment report to Congress would assess information-sharing frequency, usefulness, and potential changes to the mandate or funding.
At a Glance
What It Does
Creates the Interagency Task Force on Patents to coordinate USPTO and FDA activities on patent decisions for human drugs and biologics. Requires information sharing, MOUs, and specific processes to aid patent examiners while protecting confidential information.
Who It Affects
USPTO Director, FDA Commissioner, patent examiners, drug and biotech sponsors, and other federal agencies as coordination expands. The arrangement directly shapes how patent-related data are gathered, shared, and used in examinations and listings.
Why It Matters
This act formalizes cross-agency collaboration to improve accuracy in patent examinations for drugs and biologics, potentially reducing inconsistencies and speeding timely patent decisions while balancing confidentiality and ministerial duties.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill would add a new interagency framework to improve how patent information related to human drugs and biological products is handled. It establishes an Interagency Task Force on Patents to coordinate between the USPTO and the FDA, with membership drawn from both agencies.
The Task Force would share information about general examination processes, how applications are reviewed, and current scientific and regulatory developments that affect patent decisions. It would also facilitate sharing about new drug or biologic approvals, new technologies, and relevant prior art on a case-by-case basis.
To enable this coordination, the agencies would enter into a memorandum of understanding that clarifies duties and information-sharing approaches.
The Five Things You Need to Know
Section 14 creates the Interagency Task Force on Patents to coordinate information sharing between the USPTO and the FDA.
The Task Force will be staffed by employees from both agencies with appropriate expertise and decision-making authority.
A memorandum of understanding, or an update to an existing one, governs how the agencies carry out their duties under the Task Force.
The Act authorizes sharing of information about general patent processes, new drug approvals, and relevant prior art to support patent examination and listing activities.
A report describing information-sharing frequency, usefulness, and potential changes must be submitted to Congress within four years.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short Title
This section designates the Act as the Interagency Patent Coordination and Improvement Act of 2025. It provides the formal citation for reference in legal and policy discussions.
Findings
The findings acknowledge that patent decisions can implicate information held by other federal agencies, that applicants may share information across agencies, and that USPTO examiners benefit from access to broader data. It also encourages coordinated work between the Director of the USPTO and other federal agencies, signaling a policy preference for cross-agency collaboration.
Report on Patents Coordination
Not later than four years after enactment, the USPTO Director must report to the Judiciary Committees detailing how often FDA information is provided to examiners under the task force, how it is used in examinations, which sharing methods are most useful, recommended congressional changes, and which other agencies might coordinate with the Office in a manner similar to the FDA.
Interagency Task Force on Patents—Establishment
This section amends Chapter 1 of title 35 to establish the Interagency Task Force on Patents. It requires the Director and the FDA Commissioner to cooperate in evaluating and implementing patent-related activities for human drugs and biological products, setting the governance framework for interagency coordination.
Interagency Task Force on Patents—Operations and Access
The task force is charged with sharing information about office processes, reviewing criteria, and evaluation practices; sharing information on new patent approvals, drugs, biologics, and relevant scientific trends; and establishing a process for requesting and providing information to patent examiners. It also requires the FDA and USPTO to support examiner access to sources of product data and labeling, while maintaining confidentiality and appropriate handling to protect sensitive information.
Tables and Cross-References
The table of sections in Title 35 is amended to add Section 14, Interagency Task Force on Patents, ensuring the new framework is properly indexed in the U.S. Code.
This bill is one of many.
Codify tracks hundreds of bills on Technology across all five countries.
Explore Technology in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Director of the USPTO gains a formal mechanism to coordinate patent decisions with the FDA and to access information that can improve examination accuracy.
- USPTO patent examiners gain structured access to relevant FDA data and labeling considerations, helping them assess prior art and determine patentability more reliably.
- FDA Commissioner and agency staff participate in joint processes that align drug approvals and patent evaluations, reducing misalignment and duplication of effort.
- Pharmaceutical and biotech sponsors benefit from clearer data-sharing protocols and potentially faster, more predictable patent examinations and listings.
- Researchers and inventors in the drug and biotech space may see more consistent application of patent rules as information flows improve.
Who Bears the Cost
- USPTO and FDA resources must support the Task Force, including staff time, IT systems, and confidentiality safeguards.
- Industry sponsors may incur compliance costs to furnish information required for the joint processes and to navigate the enhanced information-sharing environment.
- Agencies must implement and maintain confidentiality protocols and access controls to protect sensitive data.
- Taxpayers and the federal budget bear indirect costs associated with expanded interagency coordination and potential system upgrades.
Key Issues
The Core Tension
The central dilemma is balancing deeper information exchange that improves patent examination quality against the need to protect confidential drug data and preserve the FDA’s separate ministerial responsibilities. Expanding cross-agency access can accelerate and improve patent determinations but risks inadvertent disclosures or overreach into non-patent functions if governance is not strict.
The bill creates a structured channel for sharing sensitive information between the USPTO and the FDA, but it also embeds guardrails to protect confidential data. While information-sharing can improve the accuracy of patent examinations for drugs and biologics, the protocols must be robust to prevent inadvertent disclosures and to maintain FDA ministerial and listing roles intact.
The duties authorize access to certain FDA information for patent examination purposes, but they also require notice to drug sponsors and clear separation of confidential information from pending patent records. The success of the approach will hinge on the effectiveness of the memoranda of understanding, the confidentiality protocols, and the governance of which information is shared and when it can be accessed by examiners.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.